cetirizine has been researched along with Sneezing in 15 studies
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.
cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.
Sneezing: The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However from 22 to 24 h after the first dose cetirizine was significantly superior to fexofenadine for the major symptom complex score and for sneezing." | 5.09 | Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. ( Burtin, B; De Vos, C; Donnelly, F; Horak, F; Kavina, A; Stübner, P; Zieglmayer, R, 2001) |
| " and intracerebroventricular pentobarbital-induced sedation and alcohol-induced ataxia models." | 3.76 | Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H. ( Bagad, AS; Bahekar, PC; Chidrewar, GU; Mandhane, SN; Mehetre, SV; Pawar, CA; Rajamannar, T; Rao, CT; Shah, JH, 2010) |
| "Levocetirizine was as effective in control of high and low symptoms except for time to achieve maximum effect (2 days versus 1 week, respectively, p = 0." | 2.75 | Clinical assessment of levocetirizine and budesonide in treatment of persistent allergic rhinitis regarding to symptom severity. ( Boonkitticharoen, V; Kulapaditharom, B; Pornprasertsuk, K, 2010) |
| "Levocetirizine treatment also correlated with a significant increase in the percentage of CD4+CD25+ T cells (P<0." | 2.73 | Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. ( Arifhodzic, N; Haines, D; Mahmoud, F; Novotney, L, 2008) |
| "Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period." | 2.71 | The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. ( Fujieda, S; Hyo, S; Kawada, R; Kitazawa, S; Takenaka, H, 2005) |
| "Cetirizine was significantly more effective at reducing the mean rhinorrhea score compared with oxatomide for both weeks 8 and 12 (P < 0." | 2.70 | The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. ( Hsieh, JC; Lai, DS; Lee, HS; Lin, KL; Lue, KH, 2002) |
| "Sneezing was also attenuated by both levocetirizine and cetirizine." | 2.70 | Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. ( Clement, P; De Vos, C; Hanotte, F; Wang, DY, 2001) |
| "Montelukast has not been reported to have major effects on sneezing and itching in the clinic but reduces nasal obstruction (lower nasal airway pressure or nasal patency)." | 1.35 | Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs. ( Al Suleimani, YM; Dong, Y; Walker, MJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitayama-Sugiyama, C | 1 |
| Mochizuki, N | 1 |
| Murata, H | 1 |
| Katsura, M | 1 |
| Kamei, C | 3 |
| Yokota, E | 1 |
| Kuyama, S | 1 |
| Sugimoto, Y | 2 |
| Ogawa, M | 1 |
| Mahmoud, F | 1 |
| Arifhodzic, N | 1 |
| Haines, D | 1 |
| Novotney, L | 1 |
| Mandhane, SN | 1 |
| Shah, JH | 1 |
| Bahekar, PC | 1 |
| Mehetre, SV | 1 |
| Pawar, CA | 1 |
| Bagad, AS | 1 |
| Chidrewar, GU | 1 |
| Rao, CT | 1 |
| Rajamannar, T | 1 |
| Kulapaditharom, B | 1 |
| Pornprasertsuk, K | 1 |
| Boonkitticharoen, V | 1 |
| Kayasuga, R | 1 |
| Watanabe, T | 1 |
| Lai, DS | 1 |
| Lue, KH | 1 |
| Hsieh, JC | 1 |
| Lin, KL | 1 |
| Lee, HS | 1 |
| Ciprandi, G | 1 |
| Tosca, MA | 1 |
| Milanese, M | 1 |
| Schenone, G | 1 |
| Ricca, V | 1 |
| Hyo, S | 1 |
| Fujieda, S | 1 |
| Kawada, R | 1 |
| Kitazawa, S | 1 |
| Takenaka, H | 1 |
| Al Suleimani, YM | 1 |
| Dong, Y | 1 |
| Walker, MJ | 1 |
| Naclerio, RM | 2 |
| Day, JH | 1 |
| Briscoe, MP | 1 |
| Clark, RH | 1 |
| Ellis, AK | 1 |
| Gervais, P | 1 |
| Wang, DY | 1 |
| Hanotte, F | 1 |
| De Vos, C | 2 |
| Clement, P | 1 |
| Horak, F | 1 |
| Stübner, P | 1 |
| Zieglmayer, R | 1 |
| Kavina, A | 1 |
| Burtin, B | 1 |
| Donnelly, F | 1 |
| Proud, D | 1 |
| Kagey-Sobotka, A | 1 |
| Freidhoff, L | 1 |
| Norman, PS | 1 |
| Lichtenstein, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis[NCT00679250] | Phase 4 | 25 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
10 trials available for cetirizine and Sneezing
| Article | Year |
|---|---|
Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis.
Topics: Adult; Anti-Inflammatory Agents; Cetirizine; Eosinophils; Female; Histamine H1 Antagonists, Non-Seda | 2008 |
Clinical assessment of levocetirizine and budesonide in treatment of persistent allergic rhinitis regarding to symptom severity.
Topics: Adult; Aged; Anti-Inflammatory Agents; Area Under Curve; Budesonide; Cetirizine; Female; Histamine H | 2010 |
The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis.
Topics: Allergens; Animals; Anti-Allergic Agents; Blood Proteins; Cetirizine; Child; Conjunctivitis, Allergi | 2002 |
Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism.
Topics: Acetates; Adolescent; Adult; Asthma; Cetirizine; Cyclopropanes; Double-Blind Method; Drug Synergism; | 2004 |
The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.
Topics: Adult; Cetirizine; Cryptomeria; Double-Blind Method; Drug Administration Schedule; Female; Histamine | 2005 |
The effect of antihistamines on the immediate allergic response: a comparative review.
Topics: Capillary Permeability; Cetirizine; Cyproheptadine; Diphenhydramine; Double-Blind Method; Histamine | 1993 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers.
Topics: Adult; Airway Resistance; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; Histamine; Hi | 2001 |
Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Bronchial Provocation Tests; Cetirizine; Cross-Over Studies; Double-Bli | 2001 |
The effect of cetirizine on early allergic response.
Topics: Albumins; Antigens; Cetirizine; Clinical Trials as Topic; Double-Blind Method; Histamine; Histamine | 1989 |
5 other studies available for cetirizine and Sneezing
| Article | Year |
|---|---|
Attenuation of histamine-induced airway effects by intranasal application of levocetirizine in mice.
Topics: Administration, Intranasal; Animals; Cetirizine; Dose-Response Relationship, Drug; Histamine; Histam | 2013 |
Participation of histamine H3 receptors in experimental allergic rhinitis of mice.
Topics: Animals; Anti-Allergic Agents; Cetirizine; Chemotaxis, Leukocyte; Disease Models, Animal; Dose-Respo | 2008 |
Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H.
Topics: Acetates; Alcohols; Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ataxia; Cetirizin | 2010 |
Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors.
Topics: Animals; Anti-Allergic Agents; Antigens; Behavior, Animal; Carbazoles; Cetirizine; Dose-Response Rel | 2002 |
Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs.
Topics: Acetates; Acute Disease; Animals; Cetirizine; Cyclopropanes; Dexamethasone; Disease Models, Animal; | 2008 |